Clinical Trial Update: An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS [Phase 4]

View source ↗

Summary

An extension Phase 4 trial evaluating efficacy and safety of HORIZANT in adolescents with moderate-to-severe primary restless legs syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Restless Legs Syndrome

Drugs mentioned

• Horizant (gabapentin enacarbil)

Snippet

Sponsor: XenoPort, Inc. | Conditions: RLS | Phase 4 | Status: UNKNOWN